{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:21:32Z","timestamp":1792797692051,"version":"4.5.0"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T00:00:00Z","timestamp":1544659200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1038\/s41571-018-0136-6","type":"journal-article","created":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T09:09:42Z","timestamp":1544692182000},"page":"227-240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":161,"title":["Somatic and germline genomics in paediatric acute lymphoblastic leukaemia"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0303-5658","authenticated-orcid":false,"given":"Ching-Hon","family":"Pui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim E.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0770-9659","authenticated-orcid":false,"given":"Jun J.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,13]]},"reference":[{"key":"136_CR1","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S2352-4642(18)30066-X","volume":"2","author":"C-H Pui","year":"2018","unstructured":"Pui, C.-H., Yang, J. J., Bhakta, N. & Rodriguez-Galindo, C. Global efforts toward the cure of childhood acute lymphoblastic leukaemia. Lancet Child Adolesc. Health 2, 440\u2013454 (2018).","journal-title":"Lancet Child Adolesc. Health"},{"key":"136_CR2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703\u2013713 (2017).","journal-title":"Nat. Med"},{"key":"136_CR3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature25480","volume":"555","author":"SN Grobner","year":"2018","unstructured":"Grobner, S. N. et al. The landscape of genomic alterations across childhood cancers. Nature 555, 321\u2013327 (2018).","journal-title":"Nature"},{"key":"136_CR4","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature25795","volume":"555","author":"X Ma","year":"2018","unstructured":"Ma, X. et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature 555, 371\u2013376 (2018).","journal-title":"Nature"},{"key":"136_CR5","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1182\/blood-2014-12-580001","volume":"125","author":"T Moriyama","year":"2015","unstructured":"Moriyama, T., Relling, M. V. & Yang, J. J. Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood 125, 3988\u20133995 (2015).","journal-title":"Blood"},{"key":"136_CR6","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa1508054","volume":"373","author":"J Zhang","year":"2015","unstructured":"Zhang, J. et al. Germline mutations in predisposition genes in pediatric cancer. N. Engl. J. Med. 373, 2336\u20132346 (2015).","journal-title":"N. Engl. J. Med."},{"key":"136_CR7","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2014.34.e44","author":"D Malkin","year":"2014","unstructured":"Malkin, D., Nichols, K. E., Zelley, K. & Schiffman, J. D. Predisposition to pediatric and hematologic cancers: a moving target. Am. Soc. Clin. Oncol. Educ. Book \n                    https:\/\/doi.org\/10.14694\/EdBook_AM.2014.34.e44\n                    \n                   (2014).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"136_CR8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","volume":"354","author":"CH Pui","year":"2006","unstructured":"Pui, C. H. & Evans, W. E. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354, 166\u2013178 (2006).","journal-title":"N. Engl. J. Med."},{"key":"136_CR9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrclinonc.2015.38","volume":"12","author":"KG Roberts","year":"2015","unstructured":"Roberts, K. G. & Mullighan, C. G. Genomics in acute lymphoblastic leukaemia: insights and treatment implications. Nat. Rev. Clin. Oncol. 12, 344\u2013357 (2015).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"136_CR10","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.clml.2017.03.299","volume":"17","author":"CH Pui","year":"2017","unstructured":"Pui, C. H., Roberts, K. G., Yang, J. J. & Mullighan, C. G. Philadelphia chromosome-like acute lymphoblastic leukemia. Clin. Lymphoma Myeloma Leuk. 17, 464\u2013470 (2017).","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"136_CR11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","volume":"10","author":"ML Boer Den","year":"2009","unstructured":"Den Boer, M. L. et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 10, 125\u2013134 (2009).","journal-title":"Lancet Oncol."},{"key":"136_CR12","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/leu.2013.317","volume":"28","author":"CJ Harrison","year":"2014","unstructured":"Harrison, C. J. et al. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia 28, 1015\u20131021 (2014).","journal-title":"Leukemia"},{"key":"136_CR13","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391\u20132405 (2016).","journal-title":"Blood"},{"key":"136_CR14","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/ng.3691","volume":"48","author":"J Zhang","year":"2016","unstructured":"Zhang, J. et al. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat. Genet. 48, 1481\u20131489 (2016).","journal-title":"Nat. Genet."},{"key":"136_CR15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/ng.3535","volume":"48","author":"T Yasuda","year":"2016","unstructured":"Yasuda, T. et al. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat. Genet. 48, 569\u2013574 (2016).","journal-title":"Nat. Genet."},{"key":"136_CR16","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11790","volume":"7","author":"H Lilljebjorn","year":"2016","unstructured":"Lilljebjorn, H. et al. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B cell precursor acute lymphoblastic leukaemia. Nat. Commun. 7, 11790 (2016).","journal-title":"Nat. Commun."},{"key":"136_CR17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ebiom.2016.04.038","volume":"8","author":"YF Liu","year":"2016","unstructured":"Liu, Y. F. et al. Genomic profiling of adult and pediatric B cell acute lymphoblastic leukemia. EBioMedicine 8, 173\u2013183 (2016).","journal-title":"EBioMedicine"},{"key":"136_CR18","volume":"7","author":"Z Gu","year":"2016","unstructured":"Gu, Z. et al. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat. Commun. 7, 13331 (2016).","journal-title":"Nat. Commun."},{"key":"136_CR19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3324\/haematol.2016.151035","volume":"102","author":"S Hirabayashi","year":"2017","unstructured":"Hirabayashi, S. et al. ZNF384-related fusion genes define a subgroup of childhood B cell precursor acute lymphoblastic leukemia with a characteristic immunotype. Haematologica 102, 118\u2013129 (2017).","journal-title":"Haematologica"},{"key":"136_CR20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1101\/gr.209163.116","volume":"27","author":"M Qian","year":"2017","unstructured":"Qian, M. et al. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP. Genome Res. 27, 185\u2013195 (2017).","journal-title":"Genome Res."},{"key":"136_CR21","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/gcc.22464","volume":"56","author":"M Zaliova","year":"2017","unstructured":"Zaliova, M. et al. ETV6\/RUNX1-like acute lymphoblastic leukemia: a novel B cell precursor leukemia subtype associated with the CD27\/CD44 immunophenotype. Genes Chromosomes Cancer 56, 608\u2013616 (2017).","journal-title":"Genes Chromosomes Cancer"},{"key":"136_CR22","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/ng.3909","volume":"49","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat. Genet. 49, 1211\u20131218 (2017).","journal-title":"Nat. Genet."},{"key":"136_CR23","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1182\/blood-2017-03-771162","volume":"129","author":"S Hu","year":"2017","unstructured":"Hu, S. et al. Whole-genome noncoding sequence analysis in T cell acute lymphoblastic leukemia identifies oncogene enhancer mutations. Blood 129, 3264\u20133268 (2017).","journal-title":"Blood"},{"key":"136_CR24","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ng.3230","volume":"47","author":"AK Andersson","year":"2015","unstructured":"Andersson, A. K. et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat. Genet. 47, 330\u2013337 (2015).","journal-title":"Nat. Genet."},{"key":"136_CR25","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1200\/JCO.2016.70.7836","volume":"35","author":"I Iacobucci","year":"2017","unstructured":"Iacobucci, I. & Mullighan, C. G. Genetic basis of acute lymphoblastic leukemia. J. Clin. Oncol. 35, 975\u2013983 (2017).","journal-title":"J. Clin. Oncol."},{"key":"136_CR26","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2013-06-509794","volume":"123","author":"A Veer van der","year":"2014","unstructured":"van der Veer, A. et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood 123, 1691\u20131698 (2014).","journal-title":"Blood"},{"key":"136_CR27","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","volume":"371","author":"KG Roberts","year":"2014","unstructured":"Roberts, K. G. et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N.\u00a0Engl. J. Med. 371, 1005\u20131015 (2014).","journal-title":"N. Engl. J. Med."},{"key":"136_CR28","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","volume":"36","author":"M Stanulla","year":"2018","unstructured":"Stanulla, M. et al. IKZF1(plus) defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia. J. Clin. Oncol. 36, 1240\u20131249 (2018).","journal-title":"J. Clin. Oncol."},{"key":"136_CR29","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/ng.2803","volume":"45","author":"V Perez-Andreu","year":"2013","unstructured":"Perez-Andreu, V. et al. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat. Genet. 45, 1494\u20131498 (2013).","journal-title":"Nat. Genet."},{"key":"136_CR30","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1200\/JCO.2018.78.3050","volume":"36","author":"AEJ Yeoh","year":"2018","unstructured":"Yeoh, A. E. J. et al. Intensifying treatment of childhood B-lymphoblastic leukemia with IKZF1 deletion reduces relapse and improves overall survival: results of malaysia-singapore ALL 2010 study. J. Clin Oncol. 36, 2726\u20132735 (2018).","journal-title":"J. Clin Oncol."},{"key":"136_CR31","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2014.55.4105","volume":"32","author":"KG Roberts","year":"2014","unstructured":"Roberts, K. G. et al. Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J. Clin. Oncol. 32, 3012\u20133020 (2014).","journal-title":"J. Clin. Oncol."},{"key":"136_CR32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/leu.2012.176","volume":"27","author":"S Jenkinson","year":"2013","unstructured":"Jenkinson, S. et al. Impact of NOTCH1\/FBXW7 mutations on outcome in pediatric T cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial. Leukemia 27, 41\u201347 (2013).","journal-title":"Leukemia"},{"key":"136_CR33","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1182\/blood-2009-02-206722","volume":"114","author":"A Gutierrez","year":"2009","unstructured":"Gutierrez, A. et al. High frequency of PTEN, PI3K, and\u00a0AKT abnormalities in T cell acute lymphoblastic leukemia. Blood 114, 647\u2013650 (2009).","journal-title":"Blood"},{"key":"136_CR34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2017-04-778829","volume":"131","author":"A Petit","year":"2018","unstructured":"Petit, A. et al. Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T cell acute lymphoblastic leukemia. Blood 131, 289\u2013300 (2018).","journal-title":"Blood"},{"key":"136_CR35","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/leu.2016.234","volume":"31","author":"CH Pui","year":"2017","unstructured":"Pui, C. H. et al. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with response-adapted therapy. Leukemia 31, 333\u2013339 (2017).","journal-title":"Leukemia"},{"key":"136_CR36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2017.176917","volume":"103","author":"G Cazzaniga","year":"2018","unstructured":"Cazzaniga, G. et al. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin\/T cell receptor and BCR\/ABL1 methodologies. Haematologica 103, 107\u2013115 (2018).","journal-title":"Haematologica"},{"key":"136_CR37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1200\/JCO.2017.74.0449","volume":"36","author":"D O\u2019Connor","year":"2018","unstructured":"O\u2019Connor, D. et al. Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia. J. Clin. Oncol. 36, 34\u201343 (2018).","journal-title":"J. Clin. Oncol."},{"key":"136_CR38","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2015-09-671131","volume":"126","author":"CG Mullighan","year":"2015","unstructured":"Mullighan, C. G. et al. Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. Blood 126, 2896\u20132899 (2015).","journal-title":"Blood"},{"key":"136_CR39","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1158\/1078-0432.CCR-17-0428","volume":"23","author":"CC Porter","year":"2017","unstructured":"Porter, C. C. et al. Recommendations for surveillance for children with leukemia-predisposing conditions. Clin. Cancer Res. 23, e14\u2013e22 (2017).","journal-title":"Clin. Cancer Res."},{"key":"136_CR40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/asheducation-2016.1.293","volume":"2016","author":"RB McGee","year":"2016","unstructured":"McGee, R. B. & Nichols, K. E. Introduction to cancer genetic susceptibility syndromes. Hematology Am. Soc. Hematol. Educ. Program 2016, 293\u2013301 (2016).","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"136_CR41","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2017-02-735290","volume":"130","author":"LA Godley","year":"2017","unstructured":"Godley, L. A. & Shimamura, A. Genetic predisposition to hematologic malignancies: management and surveillance. Blood 130, 424\u2013432 (2017).","journal-title":"Blood"},{"key":"136_CR42","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.seminoncol.2016.10.003","volume":"43","author":"S Feurstein","year":"2016","unstructured":"Feurstein, S., Drazer, M. W. & Godley, L. A. Genetic predisposition to leukemia and other hematologic malignancies. Semin. Oncol. 43, 598\u2013608 (2016).","journal-title":"Semin. Oncol."},{"key":"136_CR43","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/leu.2013.363","volume":"28","author":"F Auer","year":"2014","unstructured":"Auer, F. et al. Inherited susceptibility to pre B-ALL caused by germline transmission of PAX5 c.547\u2009G>A. Leukemia 28, 1136\u20131138 (2014).","journal-title":"Leukemia"},{"key":"136_CR44","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/ng.2754","volume":"45","author":"S Shah","year":"2013","unstructured":"Shah, S. et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat. Genet. 45, 1226\u20131231 (2013).","journal-title":"Nat. Genet."},{"key":"136_CR45","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/S1470-2045(15)00369-1","volume":"16","author":"T Moriyama","year":"2015","unstructured":"Moriyama, T. et al. Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncol. 16, 1659\u20131666 (2015).","journal-title":"Lancet Oncol."},{"key":"136_CR46","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/ng.3253","volume":"47","author":"L Noetzli","year":"2015","unstructured":"Noetzli, L. et al. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat. Genet. 47, 535\u2013538 (2015).","journal-title":"Nat. Genet."},{"key":"136_CR47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005262","volume":"11","author":"S Topka","year":"2015","unstructured":"Topka, S. et al. Germline ETV6 mutations confer susceptibility to acute lymphoblastic leukemia and thrombocytopenia. PLOS Genet. 11, e1005262 (2015).","journal-title":"PLOS Genet."},{"key":"136_CR48","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ccell.2018.03.021","volume":"33","author":"ML Churchman","year":"2018","unstructured":"Churchman, M. L. et al. Germline genetic IKZF1 variation and predisposition to childhood acute lymphoblastic leukemia. Cancer Cell 33, 937\u2013948 (2018).","journal-title":"Cancer Cell"},{"key":"136_CR49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1146\/annurev.immunol.22.012703.104807","volume":"22","author":"M Busslinger","year":"2004","unstructured":"Busslinger, M. Transcriptional control of early B cell development. Annu. Rev. Immunol. 22, 55\u201379 (2004).","journal-title":"Annu. Rev. Immunol."},{"key":"136_CR50","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nri1633","volume":"5","author":"P Matthias","year":"2005","unstructured":"Matthias, P. & Rolink, A. G. Transcriptional networks in developing and mature B cells. Nat. Rev. Immunol. 5, 497\u2013508 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"136_CR51","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/44076","volume":"401","author":"SL Nutt","year":"1999","unstructured":"Nutt, S. L., Heavey, B., Rolink, A. G. & Busslinger, M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 401, 556\u2013562 (1999).","journal-title":"Nature"},{"key":"136_CR52","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/0092-8674(94)90079-5","volume":"79","author":"P Urbanek","year":"1994","unstructured":"Urbanek, P., Wang, Z. Q., Fetka, I., Wagner, E. F. &\u00a0Busslinger, M. Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5\/BSAP. Cell 79, 901\u2013912 (1994).","journal-title":"Cell"},{"key":"136_CR53","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nature06159","volume":"449","author":"C Cobaleda","year":"2007","unstructured":"Cobaleda, C., Jochum, W. & Busslinger, M. Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature 449, 473\u2013477 (2007).","journal-title":"Nature"},{"key":"136_CR54","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/sj.leu.2404691","volume":"21","author":"RP Kuiper","year":"2007","unstructured":"Kuiper, R. P. et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia 21, 1258\u20131266 (2007).","journal-title":"Leukemia"},{"key":"136_CR55","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nature05690","volume":"446","author":"CG Mullighan","year":"2007","unstructured":"Mullighan, C. G. et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446, 758\u2013764 (2007).","journal-title":"Nature"},{"key":"136_CR56","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/leu.2008.306","volume":"23","author":"K Nebral","year":"2009","unstructured":"Nebral, K. et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 23, 134\u2013143 (2009).","journal-title":"Leukemia"},{"key":"136_CR57","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng.3177","volume":"47","author":"MY Zhang","year":"2015","unstructured":"Zhang, M. Y. et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat. Genet. 47, 180\u2013185 (2015).","journal-title":"Nat. Genet."},{"key":"136_CR58","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1101\/gad.12.15.2392","volume":"12","author":"LC Wang","year":"1998","unstructured":"Wang, L. C. et al. The TEL\/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev. 12, 2392\u20132402 (1998).","journal-title":"Genes Dev."},{"key":"136_CR59","unstructured":"Green, S. M., Coyne, H. J. 3rd, McIntosh, L. P. &\u00a0Graves, B. J. DNA binding by the ETS protein TEL\u00a0(ETV6) is regulated by autoinhibition and self-association. J. Biol. Chem. 285, 18496\u201318504 (2010)."},{"key":"136_CR60","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.13342","volume":"169","author":"L Olsson","year":"2015","unstructured":"Olsson, L. & Johansson, B. Ikaros and leukaemia. Br.\u00a0J. Haematol. 169, 479\u2013491 (2015).","journal-title":"Br. J. Haematol."},{"key":"136_CR61","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1200\/JCO.2008.21.6408","volume":"27","author":"G Martinelli","year":"2009","unstructured":"Martinelli, G. et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J. Clin. Oncol. 27, 5202\u20135207 (2009).","journal-title":"J. Clin. Oncol."},{"key":"136_CR62","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","volume":"453","author":"CG Mullighan","year":"2008","unstructured":"Mullighan, C. G. et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453, 110\u2013114 (2008).","journal-title":"Nature"},{"key":"136_CR63","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","volume":"35","author":"KG Roberts","year":"2017","unstructured":"Roberts, K. G. et al. High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J. Clin. Oncol. 35, 394\u2013401 (2017).","journal-title":"J. Clin. Oncol."},{"key":"136_CR64","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJMoa1512234","volume":"374","author":"HS Kuehn","year":"2016","unstructured":"Kuehn, H. S. et al. Loss of B cells in patients with heterozygous mutations in IKAROS. N. Engl. J. Med. 374, 1032\u20131043 (2016).","journal-title":"N. Engl. J. Med."},{"key":"136_CR65","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/leu.2017.25","volume":"31","author":"N Yoshida","year":"2017","unstructured":"Yoshida, N. et al. Germline IKAROS mutation associated with primary immunodeficiency that progressed to T cell acute lymphoblastic leukemia. Leukemia 31, 1221\u20131223 (2017).","journal-title":"Leukemia"},{"key":"136_CR66","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathol-011811-132509","volume":"7","author":"PJ McKinnon","year":"2012","unstructured":"McKinnon, P. J. ATM and the molecular pathogenesis of ataxia telangiectasia. Annu. Rev. Pathol. 7, 303\u2013321 (2012).","journal-title":"Annu. Rev. Pathol"},{"key":"136_CR67","first-page":"89","volume":"77","author":"D Morrell","year":"1986","unstructured":"Morrell, D., Cromartie, E. & Swift, M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J. Natl Cancer Inst. 77, 89\u201392 (1986).","journal-title":"J. Natl Cancer Inst."},{"key":"136_CR68","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.2014.56.5101","volume":"33","author":"F Suarez","year":"2015","unstructured":"Suarez, F. et al. Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a\u00a0report from the French national registry of primary immune deficiencies. J. Clin. Oncol. 33, 202\u2013208 (2015).","journal-title":"J. Clin. Oncol."},{"key":"136_CR69","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1182\/blood.V87.2.423.bloodjournal872423","volume":"87","author":"AM Taylor","year":"1996","unstructured":"Taylor, A. M., Metcalfe, J. A., Thick, J. & Mak, Y. F. Leukemia and lymphoma in ataxia telangiectasia. Blood 87, 423\u2013438 (1996).","journal-title":"Blood"},{"key":"136_CR70","unstructured":"Gatti, R. & Perlman, S. in GeneReviews (eds Adam, M. P. et al.) (University of Washington, 1993)."},{"key":"136_CR71","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s002470050578","volume":"29","author":"RC Murphy","year":"1999","unstructured":"Murphy, R. C. et al. Malignancies in pediatric patients with ataxia telangiectasia. Pediatr. Radiol. 29, 225\u2013230 (1999).","journal-title":"Pediatr. Radiol."},{"key":"136_CR72","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/088800101753328448","volume":"18","author":"C Sandoval","year":"2001","unstructured":"Sandoval, C., Schantz, S., Posey, D. & Swift, M. Parotid and thyroid gland cancers in patients with ataxia-telangiectasia. Pediatr. Hematol. Oncol. 18, 485\u2013490 (2001).","journal-title":"Pediatr. Hematol. Oncol."},{"key":"136_CR73","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1056\/NEJM199112263252602","volume":"325","author":"M Swift","year":"1991","unstructured":"Swift, M., Morrell, D., Massey, R. B. & Chase, C. L. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N. Engl. J. Med. 325, 1831\u20131836 (1991).","journal-title":"N. Engl. J. Med."},{"key":"136_CR74","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/cge.12710","volume":"90","author":"NJ Os van","year":"2016","unstructured":"van Os, N. J. et al. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. Clin. Genet. 90, 105\u2013117 (2016).","journal-title":"Clin. Genet."},{"key":"136_CR75","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1126\/science.7792600","volume":"268","author":"K Savitsky","year":"1995","unstructured":"Savitsky, K. et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268, 1749\u20131753 (1995).","journal-title":"Science"},{"key":"136_CR76","doi-asserted-by":"crossref","first-page":"14392","DOI":"10.1073\/pnas.212410199","volume":"99","author":"KK Hoyer","year":"2002","unstructured":"Hoyer, K. K. et al. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc.\u00a0Natl Acad. Sci. USA 99, 14392\u201314397 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"136_CR77","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000048758","volume":"69","author":"J Roos","year":"2001","unstructured":"Roos, J. et al. Expression of TCL1 in hematologic disorders. Pathobiology 69, 59\u201366 (2001).","journal-title":"Pathobiology"},{"key":"136_CR78","unstructured":"Varon, R., Demuth, I. & Chrzanowska, K. H. in GeneReviews (eds Adam, M. P. et al.) (University of Washington, 1993)."},{"key":"136_CR79","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-7-13","volume":"7","author":"KH Chrzanowska","year":"2012","unstructured":"Chrzanowska, K. H., Gregorek, H., Dembowska-Baginska, B., Kalina, M. A. & Digweed, M. Nijmegen breakage syndrome (NBS). Orphanet J. Rare Dis. 7, 13 (2012).","journal-title":"Orphanet J. Rare Dis."},{"key":"136_CR80","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s10875-015-0186-9","volume":"35","author":"B Wolska-Kusnierz","year":"2015","unstructured":"Wolska-Kusnierz, B. et al. Nijmegen breakage syndrome: clinical and immunological features, long-term outcome and treatment options - a retrospective analysis. J. Clin. Immunol. 35, 538\u2013549 (2015).","journal-title":"J. Clin. Immunol."},{"key":"136_CR81","first-page":"83","volume":"10","author":"KE Nichols","year":"2001","unstructured":"Nichols, K. E., Malkin, D., Garber, J. E., Fraumeni, J. F. Jr & Li, F. P. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol. Biomarkers Prev. 10, 83\u201387 (2001).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"136_CR82","doi-asserted-by":"crossref","first-page":"a026286","DOI":"10.1101\/cshperspect.a026286","volume":"7","author":"EQ Comeaux","year":"2017","unstructured":"Comeaux, E. Q. & Mullighan, C. G. TP53 mutations in hypodiploid acute lymphoblastic leukemia. Cold Spring Harb. Perspect. Med. 7, a026286 (2017).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"136_CR83","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/ng.2532","volume":"45","author":"L Holmfeldt","year":"2013","unstructured":"Holmfeldt, L. et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat. Genet. 45, 242\u2013252 (2013).","journal-title":"Nat. Genet."},{"key":"136_CR84","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2017.75.5215","volume":"36","author":"M Qian","year":"2018","unstructured":"Qian, M. et al. TP53 germline variations influence the predisposition and prognosis of B-cell acute lymphoblastic leukemia in children. J. Clin. Oncol. 36, 591\u2013599 (2018).","journal-title":"J. Clin. Oncol."},{"key":"136_CR85","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1158\/1078-0432.CCR-17-0574","volume":"23","author":"U Tabori","year":"2017","unstructured":"Tabori, U. et al. Clinical management and tumor surveillance recommendations of inherited mismatch repair deficiency in childhood. Clin. Cancer Res. 23, e32\u2013e37 (2017).","journal-title":"Clin. Cancer Res."},{"key":"136_CR86","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/jmedgenet-2014-102284","volume":"51","author":"K Wimmer","year":"2014","unstructured":"Wimmer, K. et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium \u2018care for CMMRD\u2019 (C4CMMRD). J. Med. Genet. 51, 355\u2013365 (2014).","journal-title":"J. Med. Genet."},{"key":"136_CR87","unstructured":"Kohlmann, W. & Gruber, S. B. in GeneReviews (eds Adam, M. P. et al.) (University of Washington, 2004)."},{"key":"136_CR88","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/jmedgenet-2015-103299","volume":"52","author":"N Lavoine","year":"2015","unstructured":"Lavoine, N. et al. Constitutional mismatch repair deficiency syndrome: clinical description in a French cohort. J. Med. Genet. 52, 770\u2013778 (2015).","journal-title":"J. Med. Genet."},{"key":"136_CR89","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/jmedgenet-2013-102238","volume":"51","author":"HF Vasen","year":"2014","unstructured":"Vasen, H. F. et al. Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium \u201cCare for CMMR-D\u201d (C4CMMR-D). J. Med. Genet. 51, 283\u2013293 (2014).","journal-title":"J. Med. Genet."},{"key":"136_CR90","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejmg.2015.12.014","volume":"59","author":"T Ripperger","year":"2016","unstructured":"Ripperger, T. & Schlegelberger, B. Acute lymphoblastic leukemia and lymphoma in the context of constitutional mismatch repair deficiency syndrome. Eur. J. Med. Genet. 59, 133\u2013142 (2016).","journal-title":"Eur. J. Med. Genet."},{"key":"136_CR91","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","volume":"34","author":"E Bouffet","year":"2016","unstructured":"Bouffet, E. et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J. Clin. Oncol. 34, 2206\u20132211 (2016).","journal-title":"J. Clin. Oncol."},{"key":"136_CR92","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.cell.2017.09.048","volume":"171","author":"BB Campbell","year":"2017","unstructured":"Campbell, B. B. et al. Comprehensive analysis of hypermutation in human cancer. Cell 171, 1042\u20131056 (2017).","journal-title":"Cell"},{"key":"136_CR93","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.canlet.2017.06.018","volume":"403","author":"H Westdorp","year":"2017","unstructured":"Westdorp, H. et al. Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome. Cancer Lett. 403, 159\u2013164 (2017).","journal-title":"Cancer Lett."},{"key":"136_CR94","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/1097-0142(19800401)45:7<1675::AID-CNCR2820450725>3.0.CO;2-D","volume":"45","author":"SR Toledano","year":"1980","unstructured":"Toledano, S. R. & Lange, B. J. Ataxia-telangiectasia and acute lymphoblastic leukemia. Cancer 45, 1675\u20131678 (1980).","journal-title":"Cancer"},{"key":"136_CR95","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/(SICI)1096-911X(199812)31:6<491::AID-MPO5>3.0.CO;2-B","volume":"31","author":"C Sandoval","year":"1998","unstructured":"Sandoval, C. & Swift, M. Treatment of lymphoid malignancies in patients with ataxia-telangiectasia. Med. Pediatr. Oncol. 31, 491\u2013497 (1998).","journal-title":"Med. Pediatr. Oncol."},{"key":"136_CR96","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1136\/adc.63.9.1079","volume":"63","author":"JA Eyre","year":"1988","unstructured":"Eyre, J. A., Gardner-Medwin, D. & Summerfield, G. P. Leukoencephalopathy after prophylactic radiation for leukaemia in ataxia telangiectasia. Arch. Dis. Child 63, 1079\u20131080 (1988).","journal-title":"Arch. Dis. Child"},{"key":"136_CR97","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1017\/S0317167100007794","volume":"36","author":"RA Yanofsky","year":"2009","unstructured":"Yanofsky, R. A. et al. Ataxia-telangiectasia: atypical presentation and toxicity of cancer treatment. Can. J. Neurol. Sci. 36, 462\u2013467 (2009).","journal-title":"Can. J. Neurol. Sci."},{"key":"136_CR98","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/jmedgenet-2011-100674","volume":"49","author":"E Schulz","year":"2012","unstructured":"Schulz, E. et al. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms. J. Med. Genet. 49, 422\u2013428 (2012).","journal-title":"J. Med. Genet."},{"key":"136_CR99","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/cncr.29615","volume":"122","author":"JE Churpek","year":"2016","unstructured":"Churpek, J. E. et al. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer 122, 304\u2013311 (2016).","journal-title":"Cancer"},{"key":"136_CR100","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s004320050258","volume":"125","author":"H Lage","year":"1999","unstructured":"Lage, H. & Dietel, M. Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J. Cancer Res. Clin. Oncol. 125, 156\u2013165 (1999).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"136_CR101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dnarep.2015.01.014","volume":"28","author":"M Olivera Harris","year":"2015","unstructured":"Olivera Harris, M. et al. Mismatch repair-dependent metabolism of O6-methylguanine-containing DNA in Xenopus laevis egg extracts. DNA Repair (Amst.) 28, 1\u20137 (2015).","journal-title":"DNA Repair (Amst"},{"key":"136_CR102","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.18632\/oncotarget.1302","volume":"4","author":"Y Shinsato","year":"2013","unstructured":"Shinsato, Y. et al. Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma. Oncotarget 4, 2261\u20132270 (2013).","journal-title":"Oncotarget"},{"key":"136_CR103","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s12094-017-1743-x","volume":"20","author":"J Stritzelberger","year":"2018","unstructured":"Stritzelberger, J., Distel, L., Buslei, R., Fietkau, R. & Putz, F. Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine. Clin. Transl Oncol. 20, 508\u2013516 (2018).","journal-title":"Clin. Transl Oncol."},{"key":"136_CR104","doi-asserted-by":"crossref","first-page":"5770","DOI":"10.1073\/pnas.081082898","volume":"98","author":"A Bardelli","year":"2001","unstructured":"Bardelli, A. et al. Carcinogen-specific induction of genetic instability. Proc. Natl Acad. Sci. USA 98, 5770\u20135775 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"136_CR105","first-page":"1","volume":"4","author":"D Fink","year":"1998","unstructured":"Fink, D., Aebi, S. & Howell, S. B. The role of DNA mismatch repair in drug resistance. Clin. Cancer Res. 4, 1\u20136 (1998).","journal-title":"Clin. Cancer Res."},{"key":"136_CR106","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med."},{"key":"136_CR107","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/ng.3508","volume":"48","author":"T Moriyama","year":"2016","unstructured":"Moriyama, T. et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat. Genet. 48, 367\u2013373 (2016).","journal-title":"Nat. Genet."},{"key":"136_CR108","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood-2017-11-815506","volume":"131","author":"R Nishii","year":"2018","unstructured":"Nishii, R. et al. Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy. Blood 131, 2466\u20132474 (2018).","journal-title":"Blood"},{"key":"136_CR109","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ng.2558","volume":"45","author":"JA Meyer","year":"2013","unstructured":"Meyer, J. A. et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat. Genet. 45, 290\u2013294 (2013).","journal-title":"Nat. Genet."},{"key":"136_CR110","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1200\/JCO.2014.59.4671","volume":"33","author":"JJ Yang","year":"2015","unstructured":"Yang, J. J. et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J. Clin. Oncol. 33, 1235\u20131242 (2015).","journal-title":"J. Clin. Oncol."},{"key":"136_CR111","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0000000000000282","volume":"27","author":"T Moriyama","year":"2017","unstructured":"Moriyama, T. et al. The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia. Pharmacogenet. Genomics 27, 236\u2013239 (2017).","journal-title":"Pharmacogenet. Genomics"},{"key":"136_CR112","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/tpj.2017.12","volume":"18","author":"Y Tanaka","year":"2018","unstructured":"Tanaka, Y. et al. Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia. Pharmacogenomics J. 18, 275\u2013280 (2018).","journal-title":"Pharmacogenomics J."},{"key":"136_CR113","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/tpj.2014.74","volume":"15","author":"Y Tanaka","year":"2015","unstructured":"Tanaka, Y. et al. Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia. Pharmacogenomics J. 15, 380\u2013384 (2015).","journal-title":"Pharmacogenomics J."},{"key":"136_CR114","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nm.3840","volume":"21","author":"B Li","year":"2015","unstructured":"Li, B. et al. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. Nat. Med. 21, 563\u2013571 (2015).","journal-title":"Nat. Med"},{"key":"136_CR115","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nature25186","volume":"553","author":"G Tzoneva","year":"2018","unstructured":"Tzoneva, G. et al. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature 553, 511\u2013514 (2018).","journal-title":"Nature"},{"key":"136_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0245-3","author":"MG Morten Tulstrup","year":"2018","unstructured":"Morten Tulstrup, M. G. et al. NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia. Leukemia \n                    https:\/\/doi.org\/10.1038\/s41375-018-0245-3\n                    \n                   (2018).","journal-title":"Leukemia"},{"key":"136_CR117","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ando.2018.03.001","volume":"79","author":"G Vitellius","year":"2018","unstructured":"Vitellius, G., Trabado, S., Bouligand, J., Delemer, B. &\u00a0Lomb\u00e8s, M. Pathophysiology of glucocorticoid signaling. Ann. Endocrinol. (Paris) 79, 98\u2013106 (2018).","journal-title":"Ann. Endocrinol. (Paris)"},{"key":"136_CR118","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/FPC.0b013e3282fc5801","volume":"18","author":"LK Kamdem","year":"2008","unstructured":"Kamdem, L. K. et al. Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia. Pharmacogenet. Genomics 18, 507\u2013514 (2008).","journal-title":"Pharmacogenet. Genomics"},{"key":"136_CR119","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1182\/blood-2015-05-643601","volume":"126","author":"SE Karol","year":"2015","unstructured":"Karol, S. E. et al. Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. Blood 126, 1770\u20131776 (2015).","journal-title":"Blood"},{"key":"136_CR120","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1182\/blood-2007-11-123885","volume":"111","author":"D French","year":"2008","unstructured":"French, D. et al. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group. Blood 111, 4496\u20134499 (2008).","journal-title":"Blood"},{"key":"136_CR121","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2015-10-673848","volume":"127","author":"SE Karol","year":"2016","unstructured":"Karol, S. E. et al. Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. Blood 127, 558\u2013564 (2016).","journal-title":"Blood"},{"key":"136_CR122","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ajpath.2013.03.004","volume":"183","author":"LJ Janke","year":"2013","unstructured":"Janke, L. J. et al. Primary epiphyseal arteriopathy in a mouse model of steroid-induced osteonecrosis. Am. J. Pathol. 183, 19\u201325 (2013).","journal-title":"Am. J. Pathol."},{"key":"136_CR123","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2010-10-311969","volume":"117","author":"JD Kawedia","year":"2011","unstructured":"Kawedia, J. D. et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 117, 2340\u20132347 (2011).","journal-title":"Blood"},{"key":"136_CR124","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.3283","volume":"47","author":"SW Paugh","year":"2015","unstructured":"Paugh, S. W. et al. NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat. Genet. 47, 607\u2013614 (2015).","journal-title":"Nat. Genet."},{"key":"136_CR125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature09727","volume":"471","author":"CG Mullighan","year":"2011","unstructured":"Mullighan, C. G. et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471, 235\u2013239 (2011).","journal-title":"Nature"},{"key":"136_CR126","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/leu.2015.359","volume":"30","author":"R Marke","year":"2016","unstructured":"Marke, R. et al. Tumor suppressor IKZF1 mediates glucocorticoid resistance in B cell precursor acute lymphoblastic leukemia. Leukemia 30, 1599\u20131603 (2016).","journal-title":"Leukemia"},{"key":"136_CR127","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2014-03-563742","volume":"124","author":"CA Fernandez","year":"2014","unstructured":"Fernandez, C. A. et al. HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood 124, 1266\u20131276 (2014).","journal-title":"Blood"},{"key":"136_CR128","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/leu.2012.102","volume":"26","author":"C Liu","year":"2012","unstructured":"Liu, C. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia 26, 2303\u20132309 (2012).","journal-title":"Leukemia"},{"key":"136_CR129","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.3324\/haematol.2017.168211","volume":"102","author":"N Kutszegi","year":"2017","unstructured":"Kutszegi, N. et al. HLA-DRB1*07:01-HLA-DQA1*02:01-HLA-DQB1*02:02 haplotype is associated with a high risk of asparaginase hypersensitivity in acute lymphoblastic leukemia. Haematologica 102, 1578\u20131586 (2017).","journal-title":"Haematologica"},{"key":"136_CR130","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1200\/JCO.2015.64.5812","volume":"34","author":"C Liu","year":"2016","unstructured":"Liu, C. et al. Clinical and genetic risk factors for acute pancreatitis in patients with acute lymphoblastic leukemia. J. Clin. Oncol. 34, 2133\u20132140 (2016).","journal-title":"J. Clin. Oncol."},{"key":"136_CR131","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/ng.2730","volume":"45","author":"H Witt","year":"2013","unstructured":"Witt, H. et al. Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat. Genet. 45, 1216\u20131220 (2013).","journal-title":"Nat. Genet."},{"key":"136_CR132","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00280-016-3236-y","volume":"79","author":"C Lanvers-Kaminsky","year":"2017","unstructured":"Lanvers-Kaminsky, C. Asparaginase pharmacology: challenges still to be faced. Cancer Chemother. Pharmacol. 79, 439\u2013450 (2017).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"136_CR133","doi-asserted-by":"crossref","first-page":"E7776","DOI":"10.1073\/pnas.1805523115","volume":"115","author":"A Nakamura","year":"2018","unstructured":"Nakamura, A. et al. Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response. Proc. Natl Acad. Sci. USA 115, E7776\u2013E7785 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"136_CR134","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2015.0894","volume":"313","author":"B Diouf","year":"2015","unstructured":"Diouf, B. et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 313, 815\u2013823 (2015).","journal-title":"JAMA"},{"key":"136_CR135","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/cpt.506","volume":"101","author":"W Stock","year":"2017","unstructured":"Stock, W. et al. An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 101, 391\u2013395 (2017).","journal-title":"Clin. Pharmacol. Ther."},{"key":"136_CR136","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","volume":"30","author":"JG Blanco","year":"2012","unstructured":"Blanco, J. G. et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes\u2014a report from the Children\u2019s Oncology Group. J. Clin. Oncol. 30, 1415\u20131421 (2012).","journal-title":"J. Clin. Oncol."},{"key":"136_CR137","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","volume":"33","author":"C-H Pui","year":"2015","unstructured":"Pui, C.-H. et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J. Clin. Oncol. 33, 2938\u20132948 (2015).","journal-title":"J. Clin. Oncol."},{"key":"136_CR138","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","volume":"360","author":"CG Mullighan","year":"2009","unstructured":"Mullighan, C. G. et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N. Engl. J. Med. 360, 470\u2013480 (2009).","journal-title":"N. Engl. J. Med."},{"key":"136_CR139","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cancergen.2011.04.005","volume":"204","author":"AE Seif","year":"2011","unstructured":"Seif, A. E. Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis. Cancer Genet. 204, 227\u2013244 (2011).","journal-title":"Cancer Genet"},{"key":"136_CR140","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0165-4608(96)00336-6","volume":"93","author":"J German","year":"1997","unstructured":"German, J. Bloom\u2019s syndrome. XX. The first 100 cancers. Cancer Genet. Cytogenet. 93, 100\u2013106 (1997).","journal-title":"Cancer Genet. Cytogenet."},{"key":"136_CR141","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2017.04.003","volume":"54","author":"E Quinn","year":"2017","unstructured":"Quinn, E. & Nichols, K. E. Cancer predisposition syndromes associated with myeloid malignancy. Semin. Hematol. 54, 115\u2013122 (2017).","journal-title":"Semin. Hematol."},{"key":"136_CR142","unstructured":"Sanz, M. M., German, J. & Cunniff, C. in GeneReviews (eds Adam, M. P. et al.) (University of Washington, 1993)."},{"key":"136_CR143","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.pcl.2014.09.009","volume":"62","author":"KW Maloney","year":"2015","unstructured":"Maloney, K. W., Taub, J. W., Ravindranath, Y., Roberts, I. & Vyas, P. Down syndrome preleukemia and leukemia. Pediatr. Clin. North Am. 62, 121\u2013137 (2015).","journal-title":"Pediatr. Clin. North Am."},{"key":"136_CR144","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pcl.2007.11.001","volume":"55","author":"MC Zwaan","year":"2008","unstructured":"Zwaan, M. C., Reinhardt, D., Hitzler, J. & Vyas, P. Acute leukemias in children with Down syndrome. Pediatr. Clin. North Am. 55, 53\u201370 (2008).","journal-title":"Pediatr. Clin. North Am."},{"key":"136_CR145","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1586\/ehm.10.14","volume":"3","author":"AC Xavier","year":"2010","unstructured":"Xavier, A. C., Ge, Y. & Taub, J. Unique clinical and biological features of leukemia in Down syndrome children. Expert Rev. Hematol. 3, 175\u2013186 (2010).","journal-title":"Expert Rev. Hematol"},{"key":"136_CR146","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.canep.2014.07.006","volume":"38","author":"G Mezei","year":"2014","unstructured":"Mezei, G., Sudan, M., Izraeli, S. & Kheifets, L. Epidemiology of childhood leukemia in the presence and absence of Down syndrome. Cancer Epidemiol. 38, 479\u2013489 (2014).","journal-title":"Cancer Epidemiol"},{"key":"136_CR147","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-016-0432-0","volume":"11","author":"V Latger-Cannard","year":"2016","unstructured":"Latger-Cannard, V. et al. Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders. Orphanet J. Rare Dis. 11, 49 (2016).","journal-title":"Orphanet J. Rare Dis."},{"key":"136_CR148","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/13793","volume":"23","author":"WJ Song","year":"1999","unstructured":"Song, W. J. et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat. Genet. 23, 166\u2013175 (1999).","journal-title":"Nat. Genet."},{"key":"136_CR149","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2015-04-641100","volume":"126","author":"JE Churpek","year":"2015","unstructured":"Churpek, J. E. et al. Genomic analysis of germ line and somatic variants in familial myelodysplasia\/acute myeloid leukemia. Blood 126, 2484\u20132490 (2015).","journal-title":"Blood"},{"key":"136_CR150","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/nyas.12346","volume":"1310","author":"AH West","year":"2014","unstructured":"West, A. H., Godley, L. A. & Churpek, J. E. Familial myelodysplastic syndrome\/acute leukemia syndromes: a review and utility for translational investigations. Ann. NY Acad. Sci 1310, 111\u2013118 (2014).","journal-title":"Ann. NY Acad. Sci"},{"key":"136_CR151","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1182\/blood-2002-07-2170","volume":"101","author":"DI Kutler","year":"2003","unstructured":"Kutler, D. I. et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 101, 1249\u20131256 (2003).","journal-title":"Blood"},{"key":"136_CR152","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2002-11-3597","volume":"101","author":"BP Alter","year":"2003","unstructured":"Alter, B. P., Greene, M. H., Velazquez, I. & Rosenberg, P. S. Cancer in Fanconi anemia. Blood 101, 2072 (2003).","journal-title":"Blood"},{"key":"136_CR153","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood-2002-05-1498","volume":"101","author":"PS Rosenberg","year":"2003","unstructured":"Rosenberg, P. S., Greene, M. H. & Alter, B. P. Cancer incidence in persons with Fanconi anemia. Blood 101, 822\u2013826 (2003).","journal-title":"Blood"},{"key":"136_CR154","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.beha.2014.10.002","volume":"27","author":"BP Alter","year":"2014","unstructured":"Alter, B. P. Fanconi anemia and the development of leukemia. Best Pract. Res. Clin. Haematol. 27, 214\u2013221 (2014).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"136_CR155","unstructured":"Mehta, P. A. & Tolar, J. in GeneReviews (eds Adam, M. P. et al.) (University of Washington, 1993)."},{"key":"136_CR156","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/bjc.1994.431","volume":"70","author":"CA Stiller","year":"1994","unstructured":"Stiller, C. A., Chessells, J. M. & Fitchett, M. Neurofibromatosis and childhood leukaemia\/lymphoma: a population-based UKCCSG study. Br. J. Cancer 70, 969\u2013972 (1994).","journal-title":"Br. J. Cancer"},{"key":"136_CR157","unstructured":"Friedman, J. M. in GeneReviews (eds Adam, M. P. et al.) (University of Washington, 1993)."},{"key":"136_CR158","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1182\/blood-2014-03-300319","volume":"124","author":"TY Chang","year":"2014","unstructured":"Chang, T. Y., Dvorak, C. C. & Loh, M. L. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia. Blood 124, 2487\u20132497 (2014).","journal-title":"Blood"},{"key":"136_CR159","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3324\/haematol.2014.114595","volume":"99","author":"CM Niemeyer","year":"2014","unstructured":"Niemeyer, C. M. RAS diseases in children. Haematologica 99, 1653\u20131662 (2014).","journal-title":"Haematologica"},{"key":"136_CR160","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejmg.2016.01.003","volume":"59","author":"H Cave","year":"2016","unstructured":"Cave, H. et al. Acute lymphoblastic leukemia in the context of RASopathies. Eur. J. Med. Genet. 59, 173\u2013178 (2016).","journal-title":"Eur. J. Med. Genet."},{"key":"136_CR161","unstructured":"Allanson, J. E. & Roberts, A. E. in GeneReviews (eds\u00a0Adam, M. P. et al.) (University of Washington,1993)."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41571-018-0136-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-018-0136-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-018-0136-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:27:31Z","timestamp":1684621651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-018-0136-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,13]]},"references-count":161,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["136"],"URL":"https:\/\/doi.org\/10.1038\/s41571-018-0136-6","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,13]]},"assertion":[{"value":"13 December 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}